Paz buys Ashdod refinery for NIS 3.25 [p.18]

October 3, 2006 22:48


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The government completed the first stage of the privatization of Oil Refineries Ltd. (Bazan) Tuesday, officially turning over the stock of the Ashdod oil refinery to Paz Oil Company in exchange for NIS 3,251,409,213. The Bazan privatization is planned to continue next year with the public offering of shares in the Haifa refinery, which Finance Minister Avraham Hirchson said would be the "largest issuing done in Israel." The Ashdod and Haifa refineries would then compete against each other as independent companies, allowing the government to stop regulating fuel prices, the ministry said. Paz wrote the NIS 3.25b. check to Bazan, which will pass on all or most of the sum to the state coffers by the end of the year. Any remaining part of the payment will revert to the Treasury with the sale of the Haifa refinery, Bazan's sole remaining asset, the ministry said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection